Holen Sie sich die Stockscreener-App
109.64
0.48%
-1.38
Handel nachbörslich:
109.84
0.20
+0.18%
Schlusskurs vom Vortag:
$108.26
Offen:
$108.26
24-Stunden-Volumen:
884.45K
Relative Volume:
1.12
Marktkapitalisierung:
$7.54B
Einnahmen:
$217.17M
Nettoeinkommen (Verlust:
$-202.68M
KGV:
-47.61
EPS:
-2.3028
Netto-Cashflow:
$-156.63M
1W Leistung:
+11.31%
1M Leistung:
+19.95%
6M Leistung:
-2.06%
1J Leistung:
+75.34%
1-Tages-Spanne:
$106.39
$111.09
1-Wochen-Bereich:
$97.44
$111.71
52-Wochen-Spanne:
$61.00
$122.20
Rhythm Pharmaceuticals Inc Stock (RYTM) Company Profile
Firmenname
Rhythm Pharmaceuticals Inc
Sektor
Branche
Telefon
857-264-4280
Adresse
222 BERKELEY STREET, BOSTON, MA
Compare RYTM vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RYTM
Rhythm Pharmaceuticals Inc
|
109.87 | 7.43B | 217.17M | -202.68M | -156.63M | -2.3028 |
VRTX
Vertex Pharmaceuticals Inc
|
490.70 | 121.87B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
632.90 | 65.01B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
887.17 | 55.26B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
291.48 | 39.14B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
182.08 | 37.88B | 742.00K | -1.37B | -1.07B | -7.0731 |
Rhythm Pharmaceuticals Inc Stock (RYTM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-19 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2025-11-25 | Eingeleitet | Citigroup | Buy |
| 2025-11-05 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2025-07-10 | Eingeleitet | Goldman | Buy |
| 2025-07-07 | Eingeleitet | Leerink Partners | Outperform |
| 2025-04-07 | Hochstufung | BofA Securities | Neutral → Buy |
| 2025-03-05 | Fortgesetzt | Stifel | Buy |
| 2025-01-02 | Eingeleitet | Jefferies | Buy |
| 2024-12-20 | Eingeleitet | Oppenheimer | Outperform |
| 2024-10-21 | Eingeleitet | Guggenheim | Buy |
| 2024-09-18 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-09-17 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2024-05-08 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-12-19 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2023-08-01 | Hochstufung | BofA Securities | Neutral → Buy |
| 2023-01-18 | Fortgesetzt | Canaccord Genuity | Buy |
| 2022-08-08 | Hochstufung | Goldman | Neutral → Buy |
| 2022-08-05 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2022-06-17 | Bestätigt | Needham | Buy |
| 2022-03-02 | Fortgesetzt | Stifel | Buy |
| 2022-02-17 | Hochstufung | Ladenburg Thalmann | Neutral → Buy |
| 2021-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2021-11-19 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-14 | Fortgesetzt | Goldman | Neutral |
| 2021-08-04 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2021-08-04 | Herabstufung | Ladenburg Thalmann | Buy → Neutral |
| 2020-11-30 | Herabstufung | BofA Securities | Buy → Neutral |
| 2020-01-08 | Eingeleitet | Goldman | Sell |
| 2019-07-12 | Hochstufung | Stifel | Hold → Buy |
| 2019-07-08 | Eingeleitet | Canaccord Genuity | Buy |
| 2019-03-13 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2018-09-07 | Fortgesetzt | Morgan Stanley | Overweight |
| 2018-06-25 | Bestätigt | Needham | Buy |
| 2018-06-15 | Bestätigt | Needham | Buy |
| 2017-10-30 | Eingeleitet | BofA/Merrill | Buy |
| 2017-10-30 | Eingeleitet | Needham | Buy |
Alle ansehen
Rhythm Pharmaceuticals Inc Aktie (RYTM) Neueste Nachrichten
Rhythm Pharmaceuticals 8-K Filing June 2026 – Company Details, Nasdaq Listing, and Executive Information - Minichart
Form 4 Rhythm Pharmaceuticals Inc For: 25 June By Investing.com - Investing.com Canada
Rhythm Pharmaceuticals (RYTM) director receives RSUs, options and converts 4,712 RSUs - Stock Titan
[Form 4] RHYTHM PHARMACEUTICALS, INC. Insider Trading Activity - Stock Titan
Director at Rhythm Pharmaceuticals (RYTM) receives new RSUs, options and exercises units - Stock Titan
Rhythm Pharmaceuticals (RYTM) director granted RSUs, stock options and converts RSUs to shares - Stock Titan
Rhythm Pharmaceuticals (RYTM) director granted RSUs, options and new shares - Stock Titan
Rhythm Pharmaceuticals (NASDAQ: RYTM) holders approve directors, pay and Ernst & Young - Stock Titan
Rhythm Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:RYTM) - TradingView
RYTM Forecast — Price Target — Prediction for 2027 - TradingView
Rhythm Pharmaceuticals(RYTM.US) Director Sells US$3.71 Million in Common Stock - Moomoo
Rhythm Pharmaceuticals (RYTM) director exercises options and sells 37,000 shares - Stock Titan
8-Day Rally Sends Rhythm Pharmaceuticals Stock Up 24% - Trefis
Rhythm Pharmaceuticals (RYTM) Stock Could Be 30.6% Undervalued on Its Growth Narrative - Sahm
Rhythm Pharmaceuticals stock surges 4.98% as RhythmPharma announces Dr. Shoemaker joins as Senior Medical Director - Traders Union
Form 144 RHYTHM PHARMACEUTICALS For: 22 June By Investing.com - Investing.com South Africa
[144] RHYTHM PHARMACEUTICALS, INC. SEC Filing - Stock Titan
Can Rhythm Pharmaceuticals (RYTM) ’s New Data Help Patients With a Rare Hunger Disorder? - Insider Monkey
Rhythm Pharmaceuticals Inc (RYTM) Institutional Confidence - TradingKey
A Quick Look at Today's Ratings for Rhythm Pharmaceuticals(RYTM.US), With a Forecast Between $105 to $155 - Moomoo
CCORF Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Raises Target Price to $151 - Moomoo
Rhythm Pharmaceuticals Inc (RYTM) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Rhythm Pharmaceuticals, Inc. (RYTM) reports Q1 loss, tops revenue estimates - MSN
Rhythm Pharmaceuticals Inc (RYTM) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Rhythm Pharmaceuticals Inc (RYTM) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Rhythm Pharmaceuticals Inc - TradingKey
Rhythm Pharmaceuticals stock price target reiterated at $130 by TD Cowen By Investing.com - Investing.com South Africa
RYTM Stock Climbs As PWS Data Drive Analyst Upgrades - StocksToTrade
Palatin Technologies Is Pursuing the Next Generation of MC4R. Rhythm Just Reinforced Why That Matters - Benzinga
(RYTM) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Rhythm Pharmaceuticals Inc (RYTM) Valuation: PE, PB & Fair Value Analysis - TradingKey
Rhythm Pharmaceuticals, Inc. (RYTM) Discusses Positive Interim Results from Phase 2 Setmelanotide Trial in Prader-Willi SyndromeSlideshow (NASDAQ:RYTM) 2026-06-17 - Seeking Alpha
RYTM News | RHYTHM PHARMACEUTICALS INC (NASDAQ:RYTM) - ChartMill
Rhythm Pharmaceuticals Inc (RYTM) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Rhythm Pharmaceuticals Inc (RYTM) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Rhythm Pharmaceuticals Inc (RYTM) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Rhythm Pharmaceuticals stock price target reiterated at $130 by TD Cowen - Investing.com South Africa
TD Cowen Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Maintains Target Price $130 - Moomoo
symbol__ Stock Quote Price and Forecast - CNN
Rhythm Pharmaceuticals posts long-term setmelanotide data for obesity - Yahoo! Finance Canada
Canaccord raises Rhythm Pharmaceuticals price target on trial data By Investing.com - Investing.com South Africa
Rhythm Pharmaceuticals: Buy Rating Reaffirmed as Strong PWS Data Lift 2033 Outlook and Price Target Raised to $151 from $143 - TipRanks
Canaccord raises Rhythm Pharmaceuticals price target on trial data - Investing.com
Citizens reiterates Rhythm Pharmaceuticals stock rating on bivamelagon data - Investing.com
Citizens reiterates Rhythm Pharmaceuticals stock rating on bivamelagon data By Investing.com - Investing.com Canada
How New Prader‑Willi Phase 2 Setmelanotide Data At Rhythm Pharmaceuticals (RYTM) Has Changed Its Investment Story - Sahm
Rhythm presents data on obesity treatments at endocrine meeting - Investing.com UK
Rhythm presents data on obesity treatments at endocrine meeting By Investing.com - Investing.com South Africa
Rhythm builds case for Phase III in Prader-Willi - biocentury.com
How This Biotech Is Taking On Genetic Obesity — And Winning - Investor's Business Daily
Rhythm Showcases Positive Setmelanotide Data Across Obesity Trials - TipRanks
Finanzdaten der Rhythm Pharmaceuticals Inc-Aktie (RYTM)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.34%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):